Physicochemical Properties
| Molecular Formula | C8H2D4O4 |
| Molecular Weight | 170.16 |
| Exact Mass | 170.052 |
| CAS # | 87976-26-9 |
| Related CAS # | Phthalic acid;88-99-3 |
| PubChem CID | 16212019 |
| Appearance | White to off-white solid powder |
| Density | 1.486g/cm3 |
| Boiling Point | 378.3ºC at 760 mmHg |
| Melting Point | 210-211ºC(lit.) |
| Flash Point | 196.7ºC |
| Index of Refraction | 1.617 |
| LogP | 1.083 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Heavy Atom Count | 12 |
| Complexity | 177 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | [2H]C1=C(C(=C(C(=C1[2H])C(=O)O)C(=O)O)[2H])[2H] |
| InChi Key | XNGIFLGASWRNHJ-RHQRLBAQSA-N |
| InChi Code | InChI=1S/C8H6O4/c9-7(10)5-3-1-2-4-6(5)8(11)12/h1-4H,(H,9,10)(H,11,12)/i1D,2D,3D,4D |
| Chemical Name | 3,4,5,6-tetradeuteriophthalic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1]. |
| References |
[1]. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Toxicological Characterization of Phthalic Acid. Toxicol Res 2011;27:191−203. |
Solubility Data
| Solubility (In Vitro) | DMSO: 100 mg/mL (587.68 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (14.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8768 mL | 29.3841 mL | 58.7682 mL | |
| 5 mM | 1.1754 mL | 5.8768 mL | 11.7536 mL | |
| 10 mM | 0.5877 mL | 2.9384 mL | 5.8768 mL |